| Ident. | Authors (with country if any) | Title |
|---|
| 000004 (2020) |
Ying Yan [République populaire de Chine] ; Le Chang [République populaire de Chine] ; Lunan Wang [République populaire de Chine] | Laboratory testing of SARS-CoV, MERS-CoV, and SARS-CoV-2 (2019-nCoV): Current status, challenges, and countermeasures. |
| 000006 (2020) |
Yang Yu [République populaire de Chine] ; Qianling Shi [République populaire de Chine] ; Peng Zheng [République populaire de Chine] ; Lei Gao [République populaire de Chine] ; Haiyuan Li [République populaire de Chine] ; Pengxian Tao [République populaire de Chine] ; Baohong Gu [République populaire de Chine] ; Dengfeng Wang [République populaire de Chine] ; Hao Chen [République populaire de Chine] | Assessment of the quality of systematic reviews on COVID-19: A comparative study of previous coronavirus outbreaks. |
| 000012 (2020) |
Yeyan He [République populaire de Chine] ; Chanying Zheng [République populaire de Chine] | [Replication and transmission mechanisms of highly pathogenic human coronaviruses]. |
| 000015 (2020) |
Muhammad Tahir Ul Qamar [République populaire de Chine] ; Safar M. Alqahtani [Arabie saoudite] ; Mubarak A. Alamri [Arabie saoudite] ; Ling-Ling Chen [République populaire de Chine] | Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants. |
| 000030 (2020) |
Bingwen Liu [République populaire de Chine] ; Min Li [République populaire de Chine] ; Zhiguang Zhou [République populaire de Chine] ; Xuan Guan [États-Unis] ; Yufei Xiang [République populaire de Chine] | Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? |
| 000035 (2019) |
Yan-Hua Li [République populaire de Chine] ; Chen-Yu Hu [République populaire de Chine] ; Nan-Ping Wu [République populaire de Chine] ; Hang-Ping Yao [République populaire de Chine] ; Lan-Juan Li [République populaire de Chine] | Molecular Characteristics, Functions, and Related Pathogenicity of MERS-CoV Proteins. |
| 000043 (2020) |
Xiaowei Li [République populaire de Chine] ; Manman Geng [République populaire de Chine] ; Yizhao Peng [République populaire de Chine] ; Liesu Meng [République populaire de Chine] ; Shemin Lu [République populaire de Chine] | Molecular immune pathogenesis and diagnosis of COVID-19. |
| 000045 (2020) |
Yu-Shi Zhang [République populaire de Chine] ; Wei-Hong Cong [République populaire de Chine] ; Jing-Jing Zhang [République populaire de Chine] ; Fei-Fei Guo [République populaire de Chine] ; Hong-Mei Li [République populaire de Chine] | [Research progress of intervention of Chinese herbal medicine and its active components on human coronavirus]. |
| 000050 (2020) |
Kaihao Liang [République populaire de Chine] | Mathematical model of infection kinetics and its analysis for COVID-19, SARS and MERS. |
| 000074 (2020) |
Xu Qian [République populaire de Chine] ; Ran Ren [République populaire de Chine] ; Youfa Wang [République populaire de Chine] ; Yan Guo [République populaire de Chine] ; Jing Fang [République populaire de Chine] ; Zhong-Dao Wu [République populaire de Chine] ; Pei-Long Liu [République populaire de Chine] ; Tie-Ru Han [République populaire de Chine] | Fighting against the common enemy of COVID-19: a practice of building a community with a shared future for mankind. |
| 000076 (2020) |
Muhammad Adnan Shereen [République populaire de Chine] ; Suliman Khan [République populaire de Chine] ; Abeer Kazmi [République populaire de Chine] ; Nadia Bashir [République populaire de Chine] ; Rabeea Siddique [République populaire de Chine] | COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. |
| 000088 (2020) |
Shibo Jiang [République populaire de Chine] ; Christopher Hillyer [États-Unis] ; Lanying Du [États-Unis] | Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses. |
| 000089 (2020) |
Mingxuan Xie [République populaire de Chine] ; Qiong Chen [République populaire de Chine] | Insight into 2019 novel coronavirus - an updated intrim review and lessons from SARS-CoV and MERS-CoV. |
| 000095 (2020) |
Song Chen [République populaire de Chine] ; Qin Yin [République populaire de Chine] ; Huibo Shi [République populaire de Chine] ; Dunfeng Du [République populaire de Chine] ; Sheng Chang [République populaire de Chine] ; Li Ni [République populaire de Chine] ; Haifang Qiu [République populaire de Chine] ; Zhishui Chen [République populaire de Chine] ; Jixian Zhang [République populaire de Chine] ; Weijie Zhang [République populaire de Chine] | A familial cluster, including a kidney transplant recipient, of Coronavirus Disease 2019 (COVID-19) in Wuhan, China. |
| 000100 (2020) |
Yuxin Yan [République populaire de Chine] ; Woo In Shin [Malaisie] ; Yoong Xin Pang [République populaire de Chine] ; Yang Meng [République populaire de Chine] ; Jianchen Lai [République populaire de Chine] ; Chong You [République populaire de Chine] ; Haitao Zhao [États-Unis] ; Edward Lester [Royaume-Uni] ; Tao Wu [République populaire de Chine] ; Cheng Heng Pang [République populaire de Chine] | The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment. |
| 000102 (2020) |
Shuntong Kang [République populaire de Chine] ; Wenyao Peng [République populaire de Chine] ; Yuhao Zhu [République populaire de Chine] ; Shiyao Lu [République populaire de Chine] ; Min Zhou [République populaire de Chine] ; Wei Lin [République populaire de Chine] ; Wenfang Wu [République populaire de Chine] ; Shu Huang [République populaire de Chine] ; Liping Jiang [République populaire de Chine] ; Xuan Luo [République populaire de Chine] ; Meichun Deng [République populaire de Chine] | Recent progress in understanding 2019 novel coronavirus (SARS-CoV-2) associated with human respiratory disease: detection, mechanisms and treatment. |
| 000104 (2020) |
Y. Shi [République populaire de Chine] ; N. Wang [République populaire de Chine] ; Q M Zou [République populaire de Chine] | [Progress and challenge of vaccine development against 2019 novel coronavirus (2019-nCoV)]. |
| 000106 (2020) |
Shengwei Yu [République populaire de Chine] ; Junwu Wang [République populaire de Chine] ; Haitao Shen [République populaire de Chine] | Network pharmacology-based analysis of the role of traditional Chinese herbal medicines in the treatment of COVID-19. |
| 000107 (2020) |
Shuai Xia [République populaire de Chine] ; Meiqin Liu [République populaire de Chine] ; Chao Wang [République populaire de Chine] ; Wei Xu [République populaire de Chine] ; Qiaoshuai Lan [République populaire de Chine] ; Siliang Feng [République populaire de Chine] ; Feifei Qi [République populaire de Chine] ; Linlin Bao [République populaire de Chine] ; Lanying Du [États-Unis] ; Shuwen Liu [République populaire de Chine] ; Chuan Qin [République populaire de Chine] ; Fei Sun [République populaire de Chine] ; Zhengli Shi [République populaire de Chine] ; Yun Zhu [République populaire de Chine] ; Shibo Jiang [République populaire de Chine] ; Lu Lu [République populaire de Chine] | Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. |
| 000108 (2020) |
Yuefei Jin [République populaire de Chine] ; Haiyan Yang [République populaire de Chine] ; Wangquan Ji [République populaire de Chine] ; Weidong Wu [République populaire de Chine] ; Shuaiyin Chen [République populaire de Chine] ; Weiguo Zhang [République populaire de Chine] ; Guangcai Duan [République populaire de Chine] | Virology, Epidemiology, Pathogenesis, and Control of COVID-19. |
| 000113 (2020) |
Liang Chen [République populaire de Chine] ; Xiangjie Li [République populaire de Chine] ; Mingquan Chen [République populaire de Chine] ; Yi Feng [République populaire de Chine] ; Chenglong Xiong [République populaire de Chine] | The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. |
